<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yang S</submitter><funding>Shanghai Municipal Science and Technology Major Project</funding><funding>Science and Technology Commission of Shanghai Municipality</funding><pagination>302</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12030110</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(4)</volume><pubmed_abstract>(1) Background: The treatment of &lt;i>Mycobacterium abscessus&lt;/i> (&lt;i>M. abscessus&lt;/i>) infections resistant to clarithromycin (CLR) is highly challenging. Traditional non-tuberculous mycobacteria (NTM) chemotherapy may disturb the immune homeostasis of the host by increasing oxidative stress; therefore, host-directed immunotherapy is an alternative option for infections caused by &lt;i>M. abscessus&lt;/i>. (2) Method: A clinical isolate of CLR-resistant &lt;i>M. abscessus&lt;/i> was screened, and then the therapeutic effects of N-acetylcysteine (NAC) against CLR-resistant &lt;i>M. abscessus&lt;/i> infection were evaluated in Tohoku Hospital Pediatrics-1 (THP-1) cells and murine models. RNA sequencing and Western blot were used to profile the protective immune responses induced by NAC. The contribution of can</pubmed_abstract><journal>Pathogens (Basel, Switzerland)</journal><pubmed_title>N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-Resistant &amp;lt;i&amp;gt;Mycobacterium abscessus&amp;lt;/i&amp;gt;.</pubmed_title><pmcid>PMC12030110</pmcid><funding_grant_id>ZD2021CY001</funding_grant_id><funding_grant_id>21Y11901700</funding_grant_id><funding_grant_id>20Z11901002</funding_grant_id><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Ma R</pubmed_authors><pubmed_authors>Fan X</pubmed_authors><pubmed_authors>Dong Y</pubmed_authors><pubmed_authors>Hu Z</pubmed_authors><pubmed_authors>Ren Y</pubmed_authors><pubmed_authors>Huang H</pubmed_authors><pubmed_authors>Li F</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Xie S</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Long Y</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Yang S</pubmed_authors></additional><is_claimable>false</is_claimable><name>N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-Resistant &amp;lt;i&amp;gt;Mycobacterium abscessus&amp;lt;/i&amp;gt;.</name><description>(1) Background: The treatment of &lt;i>Mycobacterium abscessus&lt;/i> (&lt;i>M. abscessus&lt;/i>) infections resistant to clarithromycin (CLR) is highly challenging. Traditional non-tuberculous mycobacteria (NTM) chemotherapy may disturb the immune homeostasis of the host by increasing oxidative stress; therefore, host-directed immunotherapy is an alternative option for infections caused by &lt;i>M. abscessus&lt;/i>. (2) Method: A clinical isolate of CLR-resistant &lt;i>M. abscessus&lt;/i> was screened, and then the therapeutic effects of N-acetylcysteine (NAC) against CLR-resistant &lt;i>M. abscessus&lt;/i> infection were evaluated in Tohoku Hospital Pediatrics-1 (THP-1) cells and murine models. RNA sequencing and Western blot were used to profile the protective immune responses induced by NAC. The contribution of can</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-04-08T19:43:15.717Z</modification><creation>2025-07-12T03:04:11.167Z</creation></dates><accession>S-EPMC12030110</accession><cross_references><pubmed>40333083</pubmed><doi>10.3390/pathogens14040302</doi></cross_references></HashMap>